Validating cancer drug targets

John D. Benson, Ying-Nan P. Chen, Susan A. Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R. Sellers and Christoph Lengauer ()
Additional contact information
John D. Benson: Novartis Institutes for BioMedical Research
Ying-Nan P. Chen: Novartis Institutes for BioMedical Research
Susan A. Cornell-Kennon: Novartis Institutes for BioMedical Research
Marion Dorsch: Novartis Institutes for BioMedical Research
Sunkyu Kim: Novartis Institutes for BioMedical Research
Magdalena Leszczyniecka: Novartis Institutes for BioMedical Research
William R. Sellers: Novartis Institutes for BioMedical Research
Christoph Lengauer: Novartis Institutes for BioMedical Research

Nature, 2006, vol. 441, issue 7092, 451-456

Abstract: Abstract A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as ‘validated’ before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

Date: 2006
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature04873 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:441:y:2006:i:7092:d:10.1038_nature04873

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature04873

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().